Twenty years' experience in allogeneic hematopoietic stem cell transplantation for XXXX in the Nagoya Blood and Marrow Transplantation Group.

@entity1 @entity981 @entity66 @entity2132
Between October 1981 and December 2000, 46 @entity1 with @entity981 ( @entity981 ) underwent allogeneic hematopoietic stem cell transplantation (HSCT) in the Nagoya Blood and Marrow Transplantation Group. The median age was 28.5 years (range, 4-51 years). All but one @entity1 achieved engraftment. Grade II-to-IV @entity2132 ( @entity2132 ) developed in 32.5% of @entity1 , and chronic @entity2132 developed in 40.5%. The incidences of relapse and treatment-related mortality (TRM) at 5 years were 65% and 26%, respectively. The estimated overall survival rate at 5 years was 23%. Univariate analysis showed that improved @entity66 ( @entity66 ) was independently associated with complete remission (CR) at transplantation (39%), compared with non-CR (8%) (P = .023). Non-CR at transplantation was associated with a higher risk of relapse. Donor type, acute @entity2132 , and time from diagnosis to HSCT all had a significant effect on TRM. In a multivariate analysis, 9 months or more from diagnosis to HSCT was the only variable statistically significant for @entity66 (relative risk, 3.22; P = .01). This study demonstrates that allogeneic HSCT cures a significant population of @entity1 with @entity981 . Relapse is the major obstacle limiting the success of HSCT. Early transplantation during CR from donors, including unrelated @entity1 or mismatched relatives, may offer improved long-term @entity66 .
